A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D2 receptor antagonist in the treatment of acute exacerbation of schizophrenia

European Neuropsychopharmacology

Volumn 22, Issue 10, 2012, Pages 721-733

  Schmidt, Mark E ^a   Kent, Justine M ^b   Daly, Ella ^b   Janssens, Luc ^a   Van Osselaer, Nancy ^a   Hüsken, Gitta ^c   Anghelescu, Ion George ^a   Van Nueten, Luc ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c Janssen Cilag BV Netherlands   (Netherlands)

Author keywords

Antipsychotic agents; Dopamine antagonist; JNJ 37822681; Olanzapine; Schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT; JNJ 37822681; OLANZAPINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; AGITATION; AKATHISIA; ANXIETY; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN; WELLBEING;

ACUTE DISEASE; ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INCIDENCE; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; PYRIDAZINES; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 84865534030     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.02.007     Document Type: Article

References (31)

1. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
2. Bymaster F.P., Falcone J.F. Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium. Eur. J. Pharmacol. 2000, 390(3):245-248.
3. Carlsson A., Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. (Copenh) 1963, 20:140-144.
4. Grunder G., Hippius H., Carlsson A. The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat. Rev. Drug Discov. 2009, 8(3):197-202.
5. Guy W. Clinical Global Impression Severity, Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology 1976, National Institute of Mental Health, US Department of Health, Education, and Welfare, Rockville (Maryland).
6. Guy W.E. AIMS. Abnormal Involuntary Movement Scale 1976, ECDEU National Institute of Mental Health, Rockville, Md.
7. 11C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic. Psychiatry Res. 1998, 82(3):147-160.
8. Honigfeld G., Gillis R.D., Klett C.J. NOSIE-30: a treatment-sensitive ward behavior scale. Psychol. Rep. 1966, 19(1):180-182.
9. Janssen P.A. The evolution of the butyrophenones, haloperidol and trifluperidol, from meperidine-like 4-phenylpiperidines. Int. Rev. Neurobiol. 1965, 8:221-263.
10. Kapur S., Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry 2001, 158(3):360-369.
11. Kapur S., Zipursky R.B., Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry 1999, 156(2):286-293.
12. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 2000, 157(4):514-520.
13. Karow A., Czekalla J., Dittmann R.W., Schacht A., Wagner T., Lambert M., et al. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J. Clin. Psychiatry 2007, 68(1):75-80.
14. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
15. 18F] fallypride. Neuropsychopharmacology 2008, 33(13):3111-3125.
16. Kent J., Daly E.J., Janssens L., Newcomer J.W., Van Osselaer N., Hüsken G. Metabolic and body mass parameters observed with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, versus olanzapine. American Psychiatric Association, 164th Annual Scientific Meeting, May, 2011. Honolulu - Hawaii 2011.
17. Leucht S., Kane J.M., Etschel E., Kissling W., Hamann J., Engel R.R. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006, 31(10):2318-2325.
18. Litman R.E., Su T.P., Potter W.Z., Hong W.W., Pickar D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br. J. Psychiatry 1996, 168(5):571-579.
19. Meltzer H.Y. An overview of the mechanism of action of clozapine. J. Clin. Psychiatry 1994, 55:47-52. Suppl. B.
20. Naber D., Moritz S., Lambert M., Pajonk F.G., Holzbach R., Mass R., et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr. Res. 2001, 50(1-2):79-88.
21. Nordstrom A.L., Farde L., Wiesel F.A., Forslund K., Pauli S., Halldin C., et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol. Psychiatry 1993, 33(4):227-235.
22. Obermeier M., Mayr A., Schennach-Wolff R., Seemuller F., Moller H.J., Riedel M. Should the PANSS be rescaled?. Schizophr. Bull. 2010, 36(3):455-460.
23. Pani L., Pira L., Marchese G. Antipsychotic efficacy: relationship to optimal D2-receptor occupancy. Eur. Psychiatry 2007, 22(5):267-275.
24. Schlosser R., Grunder G., Anghelescu I., Hillert A., Ewald-Grunder S., Hiemke C., et al. Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 2002, 46(1):33-40.
25. Seeman P., Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am. J. Psychiatry 1999, 156(6):876-884.
26. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
27. Tauscher J., Jones C., Remington G., Zipursky R.B., Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol. Psychiatry 2002, 7(3):317-321.
28. Te-Beek E.T., De-Boer P., Moerland M., Schmidt M., Hoetjes N.J., Windhorst A.D., et al. In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography. Journal of Psychopharmacology 2012, 2012 Feb 13 (Epub ahead of print). doi:10.1177/0269881111435251.
29. Tuppurainen H., Kuikka J.T., Viinamaki H., Husso M., Tiihonen J. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine. Psychiatry Clin. Neurosci. 2009, 63(4):529-537.
30. 11C]raclopride. Neuropsychopharmacology 2002, 27(2):248-259.
31. Zyprexa® Prescribing Information June, Accessed on September 12, 2011. http://pi.lilly.com/us/zyprexa-pi.pdf.